12 results about "Marker Antigens" patented technology

This application relates to a detection reagent, kit, and method that simultaneously improves sensitivity and broadens the detection range in competitive immunoassay. The reagent includes a detection antibody bound to luminescent microspheres that specifically binds to analyte molecules in the sample, and two sets of labeled antigens containing the same competing antigen and labeled molecules of different molecular weights bound to it. The competing antigen competes with the analyte molecule for binding to the detection antibody, and the affinity of the competing antigen for binding to the detection antibody is higher than that of the analyte molecule for binding to the detection antibody. The technical solution of this application, by using two sets of labeled antigens with different affinities, ensures that the labeled antigens that play a dominant role in samples with varying concentrations of analyte molecules differ. This is suitable for competitive immunoassay of small molecule antigens or haptens in both low-concentration and high-concentration samples, and can broaden the detection range while ensuring high functional sensitivity.

The invention relates to the field of CAR-T cell concentration detection, in particular to a method for detecting CAR-T cells through combination of microfluidics and immunofluorescence. Through immunomagnetic bead enrichment and micro-fluidic chip partitioning, CAR-T cells are separated from a blood sample through immunomagnetic beads, then labeling is carried out or enhanced by adding a labeling antigen, anti-TCR-PE and DAPI, three-channel fluorescence labeling is achieved, quantitative analysis can be carried out on the number, the cell morphology and the function of the CAR-T cells through automatic immunofluorescence imaging, and the accuracy of CAR-T cell detection is improved. And the detection limit reaches 0.001%.

The invention discloses a chemiluminiscence detection reagent for detecting an HCV antibody and a use method of the chemiluminiscence detection reagent, and relates to the technical field of immunodetection. The detection reagent is combined with a sandwich method and an indirect method for detection. When in use, a sample is incubated with the first reagent and the sample treating fluid, so that the HCV antibody to be detected in the sample reacts with the HCV coating antigen in the first reagent to form an antigen-antibody compound; adding a second reagent, and reacting the formed antigen-antibody compound with the HCV labeled antigen labeled by acridinium ester and the anti-IgG antibody labeled by acridinium ester in the second reagent to form an antigen-antibody-antigen compound and an antigen-antibody-secondary antibody compound; and finally, adding excitation liquid to enable acridinium ester to emit light, and detecting the HCV antibody in the sample by detecting a light-emitting signal value. The technical scheme of the invention greatly improves the sensitivity and specificity of HCV antibody detection, and can be used for solving the problem of easy missing detection in HCV antibody detection.

This invention proposes a microfluidic chip and its application based on dual-color and dual-layer technology to increase detection sites. The chip includes a substrate and a cover plate laminated onto the substrate. The substrate and cover plate enclose a microchannel. The microchannel is provided with a labeling region and a detection region. The labeling region includes a first labeling region on the lower surface of the cover plate and a second labeling region on the upper surface of the substrate. The detection region includes multiple detection sites on the lower surface of the cover plate and the upper surface of the substrate. The first labeling region is coated with a first labeled antigen / antibody, and the second labeling region is coated with a second labeled antigen / antibody. The first and second labeled antigens / antibodies are fluorescent microspheres labeled with two fluorophores that have the same excitation spectrum but different emission spectra. The multiple detection sites are respectively coated with capture antigens / antibodies that bind to different target analytes. By using a layered design combined with dual-color labeling, the number of simultaneously detectable indicators within the microchannel is increased.

The application discloses a fluorescence resonance energy transfer probe system and a method for high-sensitivity homogeneous immuno-detection of mycophenolic acid in whole blood. The application uses NaYbF4:Tm nanocrystals marked with BA monoclonal antibody on the surface as a donor probe, NaDyF4 nanocrystals marked with BA antigen on the surface as an acceptor probe, and constructs a fluorescence resonance energy transfer probe system. The probe system is used for qualitative and quantitative detection of mycophenolic acid in whole blood. The donor probe is incubated with a whole blood sample to be detected, and the fluorescence intensity emitted at 800 nm is tested. Then, the acceptor probe is added for joint incubation, and the fluorescence intensity emitted at 800 nm is tested. The ratio of the fluorescence intensity of the two times is compared with a control group or a standard curve, so that the mycophenolic acid in the whole blood can be qualitatively or quantitatively detected. The probe system can effectively overcome the background interference of the whole blood sample, and realize high-sensitivity homogeneous immuno-detection of BA in the whole blood.

The invention discloses a bigeminy immunoassay kit for detecting an HPV (human papillomavirus) antibody and a preparation method of the bigeminy immunoassay kit, relates to the field of biomedicine, and is characterized in that the bigeminy immunoassay kit for detecting the HPV antibody and the preparation method of the bigeminy immunoassay kit are provided. The magnetic microspheres for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 are coated with an HPV16 antibody and an HPV18 antigen, acridinium ester is used for marking the HPV16 antigen and the HPV18 antibody, an in-vitro diagnostic kit for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 is established on the basis, and a chemiluminescence immunoassay method is combined for analysis. The bigeminy immunoassay kit for quantitative detection of the HPV antibody is high in sensitivity, good in specificity, simple and convenient to operate and appropriate in price.

This invention proposes an immunomicrofluidic chip for the joint detection of IgM and IgG antibodies against the same pathogen and its application. The chip includes a substrate and a cover plate pressed onto the substrate. The substrate and cover plate together form a microchannel. From left to right, the microchannel has a labeled area and a detection area. The detection area includes an IgG detection area and an IgM detection area. The upper surface of the substrate, corresponding to the labeled area, is coated with labeled anti-human IgG antibody, and the upper surface of the substrate, corresponding to the IgG detection area, is coated with recombinant pathogen antigen. The lower surface of the cover plate, corresponding to the labeled area, is coated with labeled antigen, and the lower surface of the cover plate, corresponding to the IgM detection area, is coated with anti-human IgM antibody. By integrating the IgM antibody capture detection area and the IgG antibody indirect detection area into separate fluid layers of the chip, simultaneous but non-interfering detection of IgM and IgG antibodies in the same channel can be achieved after a single sample injection.

The invention relates to a method for labeling antigen protein by biotin. The method comprises the following steps: (1) providing a ligase compound formed by Ni < 2 + > chelated polypeptide and recombinant Turbo ID protein; (2) providing a recombinant antigen protein with HisTag (HisTag); and (3) the recombinant antigen protein with HisTag reacts with biotin in the presence of the ligase complex, ATP and Mg < 2 + > to obtain the biotin-labeled antigen protein, in the step (1), the amino acid sequence of the polypeptide is shown as SEQ ID NO: 1, and the amino acid sequence of the recombinant Turbo ID protein is shown as SEQ ID NO: 2. According to the method disclosed by the invention, the labeling efficiency when the antigen protein is labeled by biotin is improved, the biotin utilization rate is improved, and the positive detection rate of specific detection of the antibody in a clinical sample is improved.

Proposed are a disease test kit for testing a disease on the basis of a body fluid and a disease testing method using the kit, wherein the disease test kit comprises: a sample pad to which a first blocking buffer is attached and into which a body fluid sample is introduced; a conjugate pad to which a second blocking buffer is attached and which binds the body fluid sample and a labeling antibody while storing the labeling antibody; a membrane pad for detecting a concentration of a labeling antigen in the body fluid sample bound to the labeling antibody; and a test strip including an absorption pad for absorbing and storing the sample that has passed through the membrane.

This invention proposes a microfluidic chip for the combined detection of hepatitis A / hepatitis E virus IgM antibodies and its application. The chip includes a substrate and a cover plate pressed onto the substrate. The substrate and cover plate enclose a microchannel, which is provided with a labeling area and a detection area. The labeling area includes a first labeling area on the lower surface of the cover plate and a second labeling area on the upper surface of the substrate. The detection area includes an HEV-IgM antibody detection area on the lower surface of the cover plate and a HAV-IgM antibody detection area on the upper surface of the substrate. An IgG antibody capture area is provided on the upper surface of the substrate directly below the sample injection well. The IgG antibody capture area contains magnetic microspheres containing anti-human IgG antibodies. The first labeling area contains labeled HEV antigen, the second labeling area contains labeled anti-human IgM antibody, the HEV-IgM antibody detection area contains anti-human IgM antibody, and the HAV-IgM antibody detection area contains HAV antigen. The capture method and the indirect method are used in parallel to achieve the combined detection of IgM antibodies related to the two viruses.

This invention relates to the field of biotechnology, specifically to a composite quality control product for gastric tumor markers and its preparation method. The composite quality control product comprises gastric tumor marker antigens and a quality control buffer solution. The quality control buffer solution comprises 1-10% protein protectant, 0.01-3% surfactant, 2-20% thickening antioxidant, 0.5-500 mg / L protease inhibitor, 0.01-3% metal ion chelating agent, and 0.5-10% buffer matrix. The gastric tumor marker antigens include G17, PGII, and CA72-4. This invention, by addressing the interactions between G17, PGII, and CA72-4 antigens, achieves composite quality control for eight gastric tumor markers. This covers the quality control of four conventional gastric tumor detection reagents (PGI, PGII, G17, and CA72-4) and four broad-spectrum tumor detection reagents (AFP, CEA, CA19-9, and CA242), which is of significant importance for clinical gastric tumor screening.

The application relates to a method for labeling an antigen protein with biotin, which comprises the following steps: (1) providing a ligase complex formed by a polypeptide chelated with Ni 2+ and a recombinant TurboID protein; (2) providing a recombinant antigen protein with a HisTag; and (3) reacting the recombinant antigen protein with the HisTag with biotin under the condition that the ligase complex, ATP and Mg 2+ exist to obtain the antigen protein labeled with biotin, wherein the amino acid sequence of the polypeptide in the step (1) is shown in SEQ ID NO: 1, and the amino acid sequence of the recombinant TurboID protein is shown in SEQ ID NO: 2. The method improves the labeling efficiency of the antigen protein labeled with biotin, improves the biotin utilization rate, and improves the positive detection rate of specific antibody detection in a clinical sample.